ArticleCytotechnology2025

Combined anti-SPP-1 and anti-CTLA-4 immunotherapy enhances anti-tumor efficacy in hepatocellular carcinoma via IL-6/STAT3 pathway modulation.

Jin Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.